Structured products can underperform a simple stock and bond portfolio, study finds

A group of PhDs churned through 18,000 structured products issued by 13 leading banks, including Barclays, Goldman Sachs and UBS, to find out what investors in the products earned. In November, they published their results. Yakob Peterseil talks to one of the authors, Craig McCann of the Securities Litigation & Consulting Group

craig-mccann

What would happen if you took two former US Securities and Exchange Commission (SEC) economists, a couple of ex-academics and a PhD in theoretical physics, and put them in a room together with 18,000 structured products? Earlier this year, this brainy group set about analysing thousands of the products issued between 2007 and 2013 and comparing the returns to what an investor would have got from holding a portfolio of stocks and bonds. In November, they published their results.

What they found

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here